U.S. Attorney asks Novo Nordisk about plant in Denmark

Novo Nordisk ($NVO) is not a company for which regulators often express concerns over manufacturing. But the Denmark-based specialist in diabetes meds says the U.S. Attorney in Massachusetts has subpoenaed it for information about potential manufacturing issues at a plant in Kalundborg. In an email, a company spokesman said Novo has no idea what triggered the request but that it is cooperating. He said the site in Kalundborg, Denmark, comprises several plants which produce insulin, GLP-1 and factor VII. The company said, "Novo Nordisk takes patient safety and product quality very seriously and is confident in the safety of its products." Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.